Jaguar Health Files 10-Q, Details Financial Agreements

Ticker: JAGX · Form: 10-Q · Filed: 2025-05-15T00:00:00.000Z

Sentiment: neutral

Topics: 10-Q, financial-agreements, convertible-notes, equity

TL;DR

Jaguar Health 10-Q filed. Shows ongoing deals with Streeterville Capital. Watch for financial updates.

AI Summary

Jaguar Health, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details various financial instruments and agreements, including convertible notes payable and common stock transactions. Notably, it references a March 2021 Purchase Agreement and an August 2022 Purchase Agreement with Streeterville Capital, LLC, indicating ongoing financial arrangements.

Why It Matters

This filing provides insight into Jaguar Health's financial structure and ongoing commitments, which can impact investor confidence and future strategic decisions.

Risk Assessment

Risk Level: medium — The filing involves complex financial instruments and agreements, suggesting potential financial risks and uncertainties for the company.

Key Numbers

0.0167 — Five Year (Likely a financial metric or ratio, context unclear without more data)
0.04 — Five Year (Likely a financial metric or ratio, context unclear without more data)

Key Players & Entities

Jaguar Health, Inc. (company) — Filer of the 10-Q
March 2021 Purchase Agreement (agreement) — Financial agreement referenced
August 2022 Purchase Agreement (agreement) — Financial agreement referenced
Streeterville Capital, LLC (company) — Party to purchase agreements
2025-03-31 (date) — End of reporting period

FAQ

What is the nature of the "Iliad Royalty Interest" mentioned in relation to fair value measurements?

The filing references "jagx:IliadRoyaltyInterestMember" in the context of "us-gaap:FairValueInputsLevel3Member" and "us-gaap:FairValueMeasurementsRecurringMember" for dates including 2023-12-31 and 2024-12-31, indicating it's an asset valued using Level 3 inputs.

What was the purpose of the "Securities Purchase Agreement" related to convertible notes payable?

The filing mentions "jagx:SecuritiesPurchaseAgreementMember" in conjunction with "us-gaap:ConvertibleNotesPayableMember" for the period ending 2025-03-31, suggesting a transaction involving the issuance or modification of convertible debt.

What are the terms of the "March 2021 Purchase Agreement" and "August 2022 Purchase Agreement" with Streeterville Capital, LLC?

The filing notes these agreements in relation to "jagx:StreetervilleCapitalLlcMember" and specific dates (2025-03-31, 2024-01-01 to 2024-03-31, 2022-08-24), implying ongoing financial arrangements or commitments.

What is the significance of "jagx:CommonStockVotingMember" and "jagx:CommonStockMember" in the context of the filing?

These members are associated with "us-gaap:CommonStockMember" and appear in relation to purchase agreements and dates like 2025-03-31, suggesting transactions involving common stock, potentially as part of financing or equity issuances.

What is the "Equity Incentive Plan 2013" and how are stock options accounted for?

The filing references "jagx:EquityIncentivePlan2013Member" and "jagx:EmployeeAndNonemployeeStockOptionMember" for periods including 2013-11-01 to 2013-11-30 and 2023-01-01 to 2023-12-31, indicating the company's long-term incentive plans for employees and non-employees.

From the Filing

0000950170-25-072367.txt : 20250515 0000950170-25-072367.hdr.sgml : 20250515 20250515140035 ACCESSION NUMBER: 0000950170-25-072367 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 106 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250515 DATE AS OF CHANGE: 20250515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Jaguar Health, Inc. CENTRAL INDEX KEY: 0001585608 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36714 FILM NUMBER: 25951295 BUSINESS ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 415-371-8300 MAIL ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 FORMER COMPANY: FORMER CONFORMED NAME: Jaguar Animal Health, Inc. DATE OF NAME CHANGE: 20130830 10-Q 1 jagx-20250331.htm 10-Q 10-Q Q1 false 0001585608 --12-31 3 P1Y P1Y Five Year 0.0167 0.04 0 0001585608 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember jagx:IliadRoyaltyInterestMember 2023-12-31 0001585608 us-gaap:CommonStockMember jagx:CommonStockVotingMember jagx:SecuritiesPurchaseAgreementMember us-gaap:ConvertibleNotesPayableMember 2025-03-31 0001585608 jagx:March2021PurchaseAgreementMember 2024-01-01 2024-03-31 0001585608 us-gaap:FairValueInputsLevel3Member jagx:IliadRoyaltyInterestMember 2024-12-31 0001585608 jagx:August2022PurchaseAgreementMember jagx:UntilOneYearAnniversaryMember jagx:StreetervilleCapitalLlcMember 2022-08-24 0001585608 us-gaap:CommonStockMember 2024-02-27 2024-02-27 0001585608 jagx:EmployeeAndNonemployeeStockOptionMember jagx:EquityIncentivePlan2013Member 2013-11-01 2013-11-30 0001585608 us-gaap:IntersegmentEliminationMember 2025-03-31 0001585608 jagx:EmployeeAndNonemployeeStockOptionMember 2023-01-01 2023-12-31 0001585608 jagx:StreetervilleCapitalLlcMember 2025-01-01 2025-03-31 0001585608 us-gaap:MeasurementInputPriceVolatilityMember jagx:RoyaltyInterestGlobalAmendmentWarrantsMember 2023-09-29 0001585608 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember srt:MaximumMember 2025-01-01 2025-03-31 0001585608 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember jagx:StreetervilleRoyaltyInterestMember 2023-12-31 0001585608 jagx:StandstillAgreementMember jagx:StreetervilleWarrantsMember 2023-05-08 0001585608 us-gaap:FairValueInputsLevel3Member srt:WeightedAverageMember jagx:StreetervilleNoteMember jagx:SaleProceedsMember 2025-01-01 2025-03-31 0001585608 jagx:RoyaltyInterestOctober2020PurchaseAgreementMember jagx:BeginningOnOctober2021Member 2020-10-08 2020-10-08 0001585608 2023-08-14 0001585608 us-gaap:SoftwareDevelopmentMember 2025-03-31 0001585608 jagx:InsiderMember 2025-03-31 0001585608 jagx:StandstillAgreementMember jagx:StandstillWarrantsMember 2023-05-08 0001585608 jagx:SeriesGConvertiblePreferredStockMember jagx:PipeSecuritiesPurchaseAgreementMember 2023-05-08 0001585608 us-gaap:OperatingSegmentsMember 2025-01-01 2025-03-31 0001585608 jagx:BeginningOnApril2022Member jagx:RoyaltyInterestOctober2020PurchaseAgreementMember 2020-10-08 2020-10-08 0001585608 jagx:LeasedOfficePremisesSuite600Member 2025-01-01 0001585608 us-gaap:SalesRevenueNetMember srt:MinimumMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001585608 jagx:EmployeeAndNonemployeeStockOptionMember 2025-01-01 2025-03-31 0001585608 jagx:RoyaltyInterestDecember2020PurchaseAgreementMember 2020-12-22 0001585608 jagx:SeriesFPerpetualPreferredStockMember 2025-03-31 0001585608 jagx:OfficeSpaceSubLeaseMember 2021-04-06 0001585608 jagx:NewEmployeeInducementAwardPlanMember 2024-08-13 2024-08-13 0001585608 us-gaap:PatentsMember 2024-12-31 0001585608 us-gaap:FairValueInputsLevel3Member jagx:StreetervilleRoyaltyInterestMember 2024-12-31 0001585608 jagx:March2021PurchaseAgreementMember jagx:BeginningOnOctobe